Background
Results
Fructose contributes to angiogenesis in subcutaneous tumor grafts in mice
Fructose promotes VEC proliferation and inhibits apoptosis
Fructose is absorbed and metabolized by VECs and increases cell viability
Fructose enhances the migration ability and angiogenesis of VECs
Fructose regulates VEC activity through the AKT and Src signaling pathways
Expression and clinical significance of Glut5 in VECs from human colorectal cancer tissues
Variables | n | V-Glut5 | χ2 | p | |
---|---|---|---|---|---|
Negative | Positive | ||||
Age(years) | |||||
60 | 233 | 165 (36.8%) | 68 (15.2%) | 4.534 | 0.038* |
≥ 60 | 215 | 170 (37.9%) | 45 (10.0%) | ||
Gender | |||||
Male | 263 | 199 (44.4%) | 64 (14.3%) | 0.15 | 0.740 |
Female | 185 | 137 (30.6%) | 48 (10.7%) | ||
Tumor location | |||||
Colon cancer | 224 | 175 (39.1%) | 49 (10.9%) | 2.333 | 0.156 |
Rectal cancer | 224 | 160 (35.7%) | 64 (14.3%) | ||
Differentiation | |||||
well-moderate | 336 | 249 (55.6%) | 87 (19.4%) | 0.571 | 0.529 |
poor | 112 | 87 (19.4%) | 25 (5.6%) | ||
Tumor diameter | |||||
< 5 cm | 224 | 167 (37.3%) | 57 (12.7%) | 0.048 | 0.913 |
≥ 5 cm | 224 | 169 (37.7%) | 55 (12.3%) | ||
T-stage | |||||
T1-T2 | 112 | 82 (18.3%) | 30 (6.7%) | 0.254 | 0.616 |
T3-T4 | 336 | 253 (56.5%) | 83 (18.5%) | ||
N-Lymphatic metastasis | |||||
No | 296 | 225 (49.8%) | 71 (16.3%) | 0.478 | 0.492 |
Yes | 152 | 113 (25.2%) | 39 (8.7%) | ||
M | |||||
M0 | 440 | 330 (73.7%) | 110 (24.6%) | 0 | 1 |
M1 | 8 | 6 (1.3%) | 2 (0.4%) | ||
Clinical stage | |||||
I-II | 292 | 219 (48.9%) | 73 (16.3%) | 0.210 | 0.649 |
III-IV | 156 | 117 (26.1%) | 39 (8.7%) |
Variables | n | V-Glut5 | χ2 | p | |
---|---|---|---|---|---|
Negative | Positive | ||||
Age(years) | |||||
< 60 | 122 | 85 (37.9%) | 37 (16.5%) | 4.822 | 0.020* |
≥ 60 | 102 | 84 (37.5%) | 18 (8.0%) | ||
Gender | |||||
Male | 139 | 102 (45.5%) | 37 (16.5%) | 0.843 | 0.425 |
Female | 85 | 67 (29.9%) | 18 (8.0%) | ||
Tumor location | |||||
Colon | 112 | 88 (39.3%) | 24 (10.7%) | 1.181 | 0.352 |
Rectal | 112 | 81 (36.2%) | 31 (13.8%) | ||
Differentiation | |||||
well-moderate | 160 | 122 (54.5%) | 38 (17.0%) | 0.195 | 0.731 |
poor | 64 | 47 (21.0%) | 17 (7.6%) | ||
Tumor diameter | |||||
< 7 cm | 148 | 118 (37.3%) | 30 (12.7%) | 4.320 | 0.038* |
≥ 7 cm | 76 | 51 (37.7%) | 25 (12.3%) | ||
T-stage | |||||
T1-T2 | 41 | 36 (16.1%) | 5 (2.2%) | 4.138 | 0.045* |
T3-T4 | 183 | 133 (59.4%) | 50 (22.3%) | ||
N-Lymphatic metastasis | |||||
No | 145 | 114 (50.9%) | 31 (13.8%) | 2.236 | 0.146 |
Yes | 79 | 55 (24.6%) | 24 (10.7%) | ||
M-Liver metastasis | |||||
M0 | 220 | 167 (74.6%) | 53 (23.7%) | 1.424 | 0.253 |
M1 | 4 | 2 (0.9%) | 2 (0.9%) | ||
Clinical stage | |||||
I-II | 144 | 113 (50.4%) | 31 (13.8%) | 1.993 | 0.195 |
III-IV | 80 | 56 (25.0%) | 24 (10.7%) |